{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:40:07Z","timestamp":1785400807826,"version":"3.56.0"},"reference-count":88,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Background: Topical corticosteroids are essential for the management of inflammatory skin diseases but optimizing efficacy whilst minimizing adverse effects remains critical. Methylprednisolone aceponate (MPA) is a fourth-generation, non-halogenated corticosteroid developed to enhance local activity with limited systemic exposure. This review summarizes its pharmacology, clinical efficacy and safety.\n\nMethods: A PubMed search (1990\u20132025) was conducted to identify relevant studies on MPA in inflammatory dermatoses.\n\nResults: MPA\u2019s di-esterified structure and 6\u03b1-methyl modification provide potent anti-inflammatory activity with low atrophogenic potential. It is activated within the skin to a highly active metabolite and rapidly inactivated systemically, resulting in minimal systemic absorption. Clinically, MPA provides rapid pruritus relief and high clearance rates in eczematous conditions, including atopic, contact and seborrheic dermatitis. Once-daily application is generally sufficient, supporting adherence. Its availability in multiple formulations allows treatment to be tailored to lesion type and anatomical site. Longterm use is associated with a low risk of skin atrophy or hypothalamic\u2013pituitary\u2013adrenal axis suppression, and allergic sensitization is rare.\n\nConclusions: MPA offers an effective and well-tolerated option for acute and maintenance management of inflammatory skin diseases.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-revisiting-methylprednisolone-aceponate-efficacy-safety-and-current-positioning<\/jats:p>","DOI":"10.7573\/dic.2026-5-9","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:31:38Z","timestamp":1784381498000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting methylprednisolone aceponate: efficacy, safety and current positioning"],"prefix":"10.7573","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-5602","authenticated-orcid":false,"given":"Jaime","family":"Piquero-Casals","sequence":"first","affiliation":[{"name":"Department of Aesthetic Dermatology and Laser, Dermacentric Health & Aesthetics, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7929-362X","authenticated-orcid":false,"given":"Raul","family":"De Lucas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-697X","authenticated-orcid":false,"given":"Juan Francisco","family":"Mir-Bonafe\u0301","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003ez4w63","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Son Llatzer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-7868","authenticated-orcid":false,"given":"Eduardo","family":"Rozas-Mun\u0303oz","sequence":"additional","affiliation":[{"name":"Hospital San Pablo, Coquimbo, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6966-6494","authenticated-orcid":false,"given":"Sang-Chie","family":"Lin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dg86p75","id-type":"ROR","asserted-by":"publisher"}],"name":"Isdin (Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-310X","authenticated-orcid":false,"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dg86p75","id-type":"ROR","asserted-by":"publisher"}],"name":"Isdin (Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-0706","authenticated-orcid":false,"given":"Ludmila","family":"Prudkin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dg86p75","id-type":"ROR","asserted-by":"publisher"}],"name":"Isdin (Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3244-6626","authenticated-orcid":false,"given":"M\u00f3nica","family":"Foyaca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dg86p75","id-type":"ROR","asserted-by":"publisher"}],"name":"Isdin (Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-6132","authenticated-orcid":false,"given":"Daniel","family":"Morgado-Carrasco","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/021018s57","id-type":"ROR","asserted-by":"publisher"}],"name":"Universitat de Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-6035","authenticated-orcid":false,"given":"Vicente","family":"Garcia-Patos Briones","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052g8jq94","id-type":"ROR","asserted-by":"publisher"}],"name":"Universitat Aut\u00f2noma de Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017;56(6):691\u2013697. https:\/\/doi.org\/","DOI":"10.1111\/ijd.13485"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"10.1111\/ijd.13485","DOI":"10.1111\/ijd.13485"},{"key":"ref2","unstructured":"2. Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders \u2014 a clinical update. Int"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"J Clin Pract. 2006;60(1):85\u201392. https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00754.x","DOI":"10.1111\/j.1368-5031.2005.00754.x"},{"key":"ref4","unstructured":"3. Zaumseil RP, Kecsk\u00e9s A, T\u00e4uber U, T\u00f6pert M. Methylprednisolone aceponate (MPA)* \u2014 a new therapeutic for"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"eczema: a pharmacological overview. J Dermatolog Treat. 1992;3(Suppl. 2):3\u20137. https:\/\/doi.org\/","DOI":"10.3109\/09546639209092765"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"10.3109\/09546639209092765","DOI":"10.3109\/09546639209092765"},{"key":"ref7","unstructured":"4. Haneke, E. Long-term treatment with 6\u03b1-methylprednisolone aceponate. J Eur Acad Dermatol Venereol."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"1994;3:S19\u2013S22. https:\/\/doi.org\/10.1111\/j.1468-3083.1994.tb01059.x","DOI":"10.1111\/j.1468-3083.1994.tb01059.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"5. T\u00e4uber U. Pharmacokinetics and \u2018bioactivation\u2019 of MPA. J Eur Acad Dermatol Venereol. 1994;3:S23\u2013S31. https:\/\/doi.","DOI":"10.1111\/j.1468-3083.1994.tb01060.x"},{"key":"ref10","unstructured":"org\/10.1111\/j.1468-3083.1994.tb01060.x"},{"key":"ref11","unstructured":"6. Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Dermatol Venereol Leprol. 2016;82(4):371\u2013378. https:\/\/doi.org\/10.4103\/0378-6323.178903","DOI":"10.4103\/0378-6323.178903"},{"key":"ref13","unstructured":"7. Kecsk\u00e9s A, Jahn P, Lange L. Local tolerability of topically applied methylprednisolone aceponate. J Am Acad"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Dermatol. 1993;28(5 Pt 1):786\u2013788. https:\/\/doi.org\/10.1016\/s0190-9622(09)80275-2","DOI":"10.1016\/S0190-9622(09)80275-2"},{"key":"ref15","unstructured":"8. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251\u2013258. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03789.x","DOI":"10.1111\/j.1468-3083.2010.03789.x"},{"key":"ref17","unstructured":"9. Bieber T, Vick K, F\u00f6lster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1%"},{"key":"ref18","unstructured":"compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"2007;62(2):184\u2013189. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01269.x","DOI":"10.1111\/j.1398-9995.2006.01269.x"},{"key":"ref20","unstructured":"10. Ortonne JP. Skin atrophogenic potential of methylprednisolone aceponate (MPA). J Eur Acad Dermatol Venereol."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"1994;S13\u2013S18. https:\/\/doi.org\/10.1111\/j.1468-3083.1994.tb01058.x","DOI":"10.1111\/j.1468-3083.1994.tb01058.x"},{"key":"ref22","unstructured":"11. Peserico A, St\u00e4dtler G, Sebastian M, Suarez Fernandez R, Vick K, Bieber T. Reduction of relapses of atopic dermatitis"},{"key":"ref23","unstructured":"with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801\u2013807. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1365-2133.2008.08436.x"},{"key":"ref25","unstructured":"j.1365-2133.2008.08436.x"},{"key":"ref26","unstructured":"12. Khamaganova I. Alleviation of a severe pruritic flare-up in a 13-year-old child with chronic atopic dermatitis"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"treated with methylprednisolone aceponate 0.1%. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 6):20\u201321. https:\/\/","DOI":"10.1111\/j.1468-3083.2012.04715.x"},{"key":"ref28","unstructured":"doi.org\/10.1111\/j.1468-3083.2012.04715.x"},{"key":"ref29","unstructured":"13. Torrelo A. Methylprednisolone aceponate 0.1% in the treatment of pruritic lichenified eczema in a 3-year-old"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"child with chronic atopic dermatitis. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 6):18\u201319. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1468-3083.2012.04714.x"},{"key":"ref31","unstructured":"j.1468-3083.2012.04714.x"},{"key":"ref32","unstructured":"14. Machado S. Effective use of methylprednisolone aceponate 0.1% in a 9-month-old infant with atopic eczema"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"and sleep disturbance. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 6):14\u201315. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1468-3083.2012.04712.x"},{"key":"ref34","unstructured":"j.1468-3083.2012.04712.x"},{"key":"ref35","unstructured":"15. Garc\u00eda Ponte L, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Dermatol Venereol. 2012;26(Suppl. 6):9\u201313. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04711.x","DOI":"10.1111\/j.1468-3083.2012.04711.x"},{"key":"ref37","unstructured":"16. Sekine R, Satoh T, Takaoka A, Saeki K, Yokozeki H. Anti pruritic effects of topical crotamiton, capsaicin, and a"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"corticosteroid on pruritogen-induced scratching behavior. Exp Dermatol. 2012;21(3):201\u2013204. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1600-0625.2011.01433.x"},{"key":"ref39","unstructured":"j.1600-0625.2011.01433.x"},{"key":"ref40","unstructured":"17. Thomova T, Jedlickova H, Bohm J, Holochova P, Ruzicka F, Borilova Linhartova P. Effect of systemic therapies on skin"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"bacteriome in patients with atopic dermatitis: a pilot prospective study. J Invest Dermatol. 2026;146(2):483\u2013492.e8.","DOI":"10.1016\/j.jid.2025.07.006"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2025.07.006","DOI":"10.1016\/j.jid.2025.07.006"},{"key":"ref43","unstructured":"18. Lachapelle JM, Gimenez-Arnau A, Metz M, Peters J, Proksch E. Best practices, new perspectives and the perfect"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"emollient: optimizing the management of contact dermatitis. J Dermatolog Treat. 2018;29(3):241\u2013251. https:\/\/doi.org\/","DOI":"10.1080\/09546634.2017.1370074"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"10.1080\/09546634.2017.1370074","DOI":"10.1080\/09546634.2017.1370074"},{"key":"ref46","unstructured":"19. Curto L, Carnero L, L\u00f3pez-Aventin D, Traveria G, Roura G, Gim\u00e9nez-Arnau AM. Fast itch relief in an experimental"},{"key":"ref47","unstructured":"model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"nickel sulphate. J Eur Acad Dermatol Venereol. 2014;28(10):1356\u20131362. https:\/\/doi.org\/10.1111\/jdv.12292","DOI":"10.1111\/jdv.12292"},{"key":"ref49","unstructured":"20. Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and"},{"key":"ref50","unstructured":"metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Treat. 2009;20(6):344\u2013349. https:\/\/doi.org\/10.3109\/09546630802687349","DOI":"10.3109\/09546630802687349"},{"key":"ref52","unstructured":"21. Staubach P, Mann C, Hagenstr\u00f6m K, Augustin M. Versorgung und Krankheitskosten der Urtikaria bei Kindern in"},{"key":"ref53","unstructured":"Deutschland: Arzneimittel, \u00e4rztliche und station\u00e4re Leistungen [Care and medical costs of urticaria in children"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"in Germany: Drugs, medical and inpatient services]. Dermatologie. 2024;75(7):554\u2013561. https:\/\/doi.org\/10.1007\/","DOI":"10.1007\/s00105-024-05346-3"},{"key":"ref55","unstructured":"s00105-024-05346-3"},{"key":"ref56","unstructured":"22. Chung JW, Kim HT, Jang SW, et al. Comparison of the effect of steroids on the treatment of phimosis according to"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"the steroid potencies. Urol J. 2021;18(6):652\u2013657. https:\/\/doi.org\/10.22037\/uj.v18i.6574","DOI":"10.1080\/14490854.2021.1988662"},{"key":"ref58","unstructured":"23. Sava\u015f Erdo\u011fan S, Cebeci Kahraman F. Fixed drug eruption after pentavalent diphtheria, tetanus, acellular"},{"key":"ref59","unstructured":"pertussis, inactivated poliovirus and Haemophilus influenzae type B combined vaccine in an infant. Eur J Hosp"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Pharm. 2023;30(4):e16. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002875","DOI":"10.1136\/ejhpharm-2021-002875"},{"key":"ref61","unstructured":"24. Ricciardi AS, Chedid MF, Thompson CE, Silva RKD, Azulay DR, Manela-Azulay M. Randomized clinical trial comparing"},{"key":"ref62","unstructured":"removal followed by topical imiquimod versus removal followed by topical methylprednisolone in the treatment"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"of keloids. Acta Cir Bras. 2025;40:e406225. https:\/\/doi.org\/10.1590\/acb406225","DOI":"10.1590\/acb406225"},{"key":"ref64","unstructured":"25. Wohlrab J, Neubert RH, Sommer E, Michael J. Clotrimazol und Ciclopiroxolamin jeweils in Kombination mit"},{"key":"ref65","unstructured":"Methylprednisolonaceponat in magistralen Rezepturen [Clotrimazole and ciclopirox olamine respectively in"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"combination with methylprednisolone aceponate as extemporaneous formulations]. Hautarzt. 2017;68(4):307\u2013315.","DOI":"10.1007\/s00105-016-3926-8"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-016-3926-8","DOI":"10.1007\/s00105-016-3926-8"},{"key":"ref68","unstructured":"26. Pekmezci E. A novel triple combination in treatment of melasma: significant outcome with far less actives. J"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Cosmet Dermatol. 2019;18(6):1700\u20131704. https:\/\/doi.org\/10.1111\/jocd.12904","DOI":"10.1111\/jocd.12904"},{"key":"ref70","unstructured":"27. Rampini E. Methylprenisolone aceponate (MPA)* \u2014 use and clinical experience in children. J Dermatolog Treat."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"1992;3(Suppl. 2):27\u201329. https:\/\/doi.org\/10.3109\/09546639209092770","DOI":"10.3109\/09546639209092770"},{"key":"ref72","unstructured":"28. Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit\/risk"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(5):508\u2013515. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1468-3083.2010.03942.x"},{"key":"ref74","unstructured":"j.1468-3083.2010.03942.x"},{"key":"ref75","unstructured":"29. Gregersen DM, Peckruhn M, Breternitz-Gruhne M, et al. Cream versus ointment: randomized single-blinded study"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"on the adherence to treatment with topical methylprednisolone aceponate. Contact Dermatitis. 2024;90(2):161\u2013","DOI":"10.1111\/cod.14447"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"168. https:\/\/doi.org\/10.1111\/cod.14447","DOI":"10.1111\/cod.14447"},{"key":"ref78","unstructured":"30. Mercader-Garc\u00eda P, Pastor-Nieto MA, Garc\u00eda-Doval I, et al. Are the Spanish baseline series markers sufficient to"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study. Contact Dermatitis. 2018;78(1):76\u2013","DOI":"10.1111\/cod.12874"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"82. https:\/\/doi.org\/10.1111\/cod.12874","DOI":"10.1111\/cod.12874"},{"key":"ref81","unstructured":"31. Aschoff R, Lang A, Koch E. Effects of intermittent treatment with topical corticosteroids and calcineurin inhibitors"},{"key":"ref82","unstructured":"on epidermal and dermal thickness using optical coherence tomography and ultrasound. Skin Pharmacol Physiol."},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"2022;35(1):41\u201350. https:\/\/doi.org\/10.1159\/000518214","DOI":"10.1159\/000518214"},{"key":"ref84","unstructured":"32. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818\u2013823. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.005","DOI":"10.1016\/j.jaci.2014.08.005"},{"key":"ref86","unstructured":"33. Mensing H, Lorenz B. Experience with methylprednisolone aceponate (MPA) in patients suffering from acute and"},{"key":"ref87","unstructured":"chronic eczema. Results of a large observational study. Z Hautkr. 1998;73:281\u2013285."}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/07\/dic.2026-5-9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:31:49Z","timestamp":1784381509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/revisiting-methylprednisolone-aceponate-efficacy-safety-and-current-positioning"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-5-9","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"2026-5-9"}}